StreetInsider.com News Articles

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Tue, 21 Jul 2026 07:30:00 -0400

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare disease

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Tue, 21 Jul 2026 07:30:00 -0400

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare disease

Form 4 Rezolute, Inc. For: Jul 02 Filed by: ROBERTS BRIAN KENNETH

Tue, 07 Jul 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20260707/26742964.html

Form 4 Rezolute, Inc. For: Jul 02 Filed by: ROBERTS BRIAN KENNETH

Tue, 07 Jul 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20260707/26742964.html

Form 4 Rezolute, Inc. For: Jul 02 Filed by: Elam Nevan C

Tue, 07 Jul 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260707/26742790.html

Form 4 Rezolute, Inc. For: Jul 02 Filed by: Elam Nevan C

Tue, 07 Jul 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260707/26742790.html

Form 4 Rezolute, Inc. For: Jul 02 Filed by: Evans Daron

Tue, 07 Jul 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260707/26742775.html

Form 4 Rezolute, Inc. For: Jul 02 Filed by: Evans Daron

Tue, 07 Jul 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260707/26742775.html

Rezolute presents hyperinsulinism data at Endocrine Society meeting

Wed, 17 Jun 2026 07:03:21 -0400

Rezolute, Inc. (Nasdaq: RZLT) presented four data analyses at the Annual Meeting of the Endocrine Society, covering natural history outcomes in congenital hyperinsulinism (HI) and clinical results from its ersodetug program.

Two poster presentations examined the natural history and adverse outcomes of congenital HI, using a meta-analysis of existing literature and a claims-based analysis to quantify disease complications. A third poster reported results from a case series of nine patients with refractory hypoglycemia due to malignant insulinoma and non-islet cell tumors enrolled in the company's Expanded Access Program. According to the press release, 75% of those patients receiving intravenous dextrose or

Rezolute presents hyperinsulinism data at Endocrine Society meeting

Wed, 17 Jun 2026 07:03:21 -0400

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Wed, 17 Jun 2026 07:00:00 -0400

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company’s Phase 3 sunRIZE study in congenital HI and a case series from its Expanded Access Program (EAP) in tumor HI

REDWOOD CITY, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today highlighted four data presentations delivered at the Annual Meeting of the Endocrine Society (ENDO).

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Wed, 17 Jun 2026 07:00:00 -0400

Rezolute (RZLT) PT Raised to $11 at Guggenheim

Mon, 15 Jun 2026 06:53:13 -0400

(Updated - June 15, 2026 6:53 AM EDT)

Guggenheim analyst Debjit Chattopadhyay raised the price target on Rezolute (NASDAQ: RZLT) to $11.00 (from $6.00) while maintaining a Buy rating.

The analyst commented: "We are increasing our PT to $11, i.e., ~175% potential upside from the current level. Our thesis is based on the high likelihood of a positive readout from the upLIFT registrational study during 2H26. Recall, the recent interim update, mechanistically and clinically de-risks the upLIFT readout. We model ~$850M in peak sales in the U.S. alone (at $750k gross and $540k compliance-adjusted net WAC) in tHI, which is backed by

Rezolute (RZLT) PT Raised to $11 at Guggenheim

Mon, 15 Jun 2026 06:53:13 -0400

(Updated - June 15, 2026 6:53 AM EDT)

Guggenheim analyst Debjit Chattopadhyay raised the price target on Rezolute (NASDAQ: RZLT) to $11.00 (from $6.00) while maintaining a Buy rating.

Rezolute (RZLT) PT Raised to $13 at H.C. Wainwright

Mon, 15 Jun 2026 06:52:23 -0400

H.C. Wainwright analyst Douglas Tsao raised the price target on Rezolute (NASDAQ: RZLT) to $13.00 (from $10.00) while maintaining a Buy rating.

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society